Imagion Biosystems has announced receipt of its 2019 R&D tax incentive claim of A$2,197,028 from the Australian Tax Office (ATO). In May 2019 the Company
Imagion Biosystems Limited (ASX:IBX) is pleased to confirm that the rights the subject of the Company’s Renounceable Rights Issue announced on Wednesday, 25 March 2020,
Imagion Biosystems Limited has accepted the resignation of non-executive director Bronwyn Le Grice. Ms Le Grice’s resignation is effective March 31st, 2020. Read Imagion Biosystems
Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus: For a renounceable pro rata offer of 204,512,879 Shares at an issue price of $0.01
Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.
Imagion Biosystems Limited has released “Pro-Rata Renounceable Rights Issue”. Highlight of this issue include: Funds to complete the manufacture of nanoparticle material and initiate a
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX
Imagion Biosystems Limited wishes to advise that its Australian registered office address has changed with immediate effect to: c/o K&L Gates, Level 25, 525 Collins Street,
President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA
Appendix 4E and 2019 Full Year Results Key Developments Achieved for MagSense® Imaging Technology Imagion Biosystems has released its Appendix 4E and Preliminary Results for
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance